Erratum to: Disruption of human papillomavirus 16 E6 gene by clustered regularly interspaced short palindromic repeat/Cas system in human cervical cancer cells (OncoTargets and Therapy., (2015) 8, (37-44), 10.2147/OTT.S64092);Disruption of human papillomavirus 16 E6 gene by clustered regularly interspaced short palindromic repeat/Cas system in human cervical cancer cells

OncoTargets and Therapy

Volumn 8, Issue , 2014, Pages 37-44

  Yu, Lan ^a   Wang, Xiaoli ^a   Zhu, Da ^a   Ding, Wencheng ^a   Wang, Liming ^a   Zhang, Changlin ^a   Jiang, Xiaohui ^a   Shen, Hui ^a   Liao, Shujie ^a   Ma, Ding ^a   Hu, Zheng ^a   Wang, Hui ^a  

^a HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

Author keywords

CaSki; Cervical cancer; CRISPR Cas system; E6; P53; SiHa

Indexed keywords

CRISPR ASSOCIATED PROTEIN; DNA; ENDONUCLEASE; PROTEIN E6; PROTEIN P53;

ANTIBODY SPECIFICITY; APOPTOSIS; ARTICLE; CELL PROLIFERATION; CERVICAL CANCER CELL LINE; CONTROLLED STUDY; DNA CLEAVAGE; DOWN REGULATION; E6 GENE; ENZYME SPECIFICITY; GENE CLUSTER; GENE DISRUPTION; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; HUMAN PAPILLOMAVIRUS TYPE 16; IMMUNOPRECIPITATION; NONHUMAN; PLASMID; POLYMERASE CHAIN REACTION; PROTEIN CLEAVAGE; RNA SYNTHESIS; STOP CODON; VIRUS GENE;

EID: 84919787502     PISSN: None     EISSN: 11786930     Source Type: Journal    
DOI: 10.2147/OTT.S142877     Document Type: Erratum

References (22)

1. Armstrong EP. Prophylaxis of cervical cancer and related cervical disease: a review of the cost-effectiveness of vaccination against oncogenic HPV types. J Manag Care Pharm. 2010;16:217-230.
2. Clifford GM, Smith JS, Plummer M, Muñoz N, Franceschi S. Human papillomavirus types in invasive cervical cancer worldwide: a meta-analysis. Br J Cancer. 2003;88:63-73.
3. zur Hausen H. Papillomaviruses and cancer: from basic studies to clinical application. Nat Rev Cancer. 2002;2:342-350.
4. Talora C, Sgroi DC, Crum CP, Dotto GP. Specific down-modulation of Notch1 signaling in cervical cancer cells is required for sustained HPV-E6/E7 expression and late steps of malignant transformation. Genes Dev. 2002;16:2252-2263.
5. Mali P, Yang L, Esvelt KM, et al. RNA-guided human genome engineering via Cas9. Science. 2013;339:823-826.
6. Barrangou R, Fremaux C, Deveau H, et al. CRISPR provides acquired resistance against viruses in prokaryotes. Science. 2007;315:1709-1712.
7. Katic I, Großhans H. Targeted heritable mutation and gene conversion by Cas9-CRISPR in Caenorhabditis elegans. Genetics. 2013;195:1173-1176.
8. Hwang WY, Fu Y, Reyon D, et al. Efficient genome editing in zebrafish using a CRISPR-Cas system. Nat Biotechnol. 2013;31:227-229.
9. Rassool FV. DNA double strand breaks (DSB) and non-homologous end joining (NHEJ) pathways in human leukemia. Cancer Lett. 2003;193:1-9.
10. Santiago Y, Chan E, Liu PQ, et al. Targeted gene knockout in mammalian cells by using engineered zinc-finger nucleases. Proc Natl Acad Sci U S A. 2008;105:5809-5814.
11. Cho SW, Kim S, Kim JM, Kim JS. Targeted genome engineering in human cells with the Cas9 RNA-guided endonuclease. Nat Biotechnol. 2013;31:230-232.
12. Bhakta MS, Segal DJ. The generation of zinc finger proteins by modular assembly. Methods Mol Biol. 2010;649:3-30.
13. Kim HJ, Lee HJ, Kim H, Cho SW, Kim JS. Targeted genome editing in human cells with zinc finger nucleases constructed via modular assembly. Genome Res. 2009;19:1279-1288.
14. Zanier K, Charbonnier S, Baltzinger M, Nominé Y, Altschuh D, Travé G. Kinetic analysis of the interactions of human papillomavirus E6 oncoproteins with the ubiquitin ligase E6AP using surface plasmon resonance. J Mol Biol. 2005;349:401-412.
15. Talis AL, Huibregtse JM, Howley PM. The role of E6AP in the regulation of p53 protein levels in human papillomavirus (HPV)-positive and HPV-negative cells. J Biol Chem. 1998;273:6439-6445.
16. Jonson AL, Rogers LM, Ramakrishnan S, Downs LS Jr. Gene silencing with siRNA targeting E6/E7 as a therapeutic intervention in a mouse model of cervical cancer. Gynecol Oncol. 2008;111:356-364.
17. Castanotto D, Rossi JJ, The promises and pitfalls of RNA-interference-based therapeutics. Nature. 2009;457:426-433.
18. Tang S, Tao M, McCoy JP Jr, Zheng ZM. Short-term induction and long-term suppression of HPV16 oncogene silencing by RNA interference in cervical cancer cells. Oncogene. 2006;25:2094-2104.
19. Heidenreich E, Novotny R, Kneidinger B, Holzmann V, Wintersberger U. Non-homologous end joining as an important mutagenic process in cell cycle-arrested cells. EMBO J. 2003;22:2274-2283.
20. Li D, Qiu Z, Shao Y, et al. Heritable gene targeting in the mouse and rat using a CRISPR-Cas system. Nat Biotechnol. 2013;31:681-683.
21. Mussolino C, Cathomen T. RNA guides genome engineering. Nat Biotechnol. 2013;31:208-209.
22. Ran FA, Hsu PD, Lin CY, et al. Double nicking by RNA-guided CRISPR Cas9 for enhanced genome editing specificity. Cell. 2013;154:1380-1389.